CBUS
$3.68
Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products.
Recent News
Cibus (CBUS) Q4 2025 Earnings Call Transcript
By any measure, 2025 was a landmark year for Cibus, Inc., not because of any single headline, but because of a convergence of key themes that are shaping the trajectory of the gene editing industry. Gene editing is no longer an experiment. What makes this current moment particularly exciting is the intersection of our technology readiness and a change in how we believe seed companies are thinking about gene editing.
Cibus (CBUS) Reports Q4 Loss, Lags Revenue Estimates
Cibus (CBUS) delivered earnings and revenue surprises of +2.33% and -27.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Cibus: Q4 Earnings Snapshot
SAN DIEGO (AP) — Cibus, Inc. CBUS) on Tuesday reported a loss of $31.3 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 59 cents.
Mission Produce, Inc. (AVO) Surpasses Q1 Earnings Estimates
Mission Produce (AVO) delivered earnings and revenue surprises of +42.86% and -7.90%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?
Cibus, Inc. (NASDAQ:CBUS) surges 15%; individual investors who own 43% shares profited along with insiders
Key Insights Significant control over Cibus by individual investors implies that the general public has more power to...